Ron Bose
Washington University in St. Louis · 333 works · 19,193 citations · h-index 48
Top works
- Comprehensive genomic characterization of squamous cell lung cancers
- Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- Human Proteinpedia enables sharing of human protein data
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- DGIdb: mining the druggable genome
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
- Ceramide Generation by the Reaper Protein Is Not Blocked by the Caspase Inhibitor, p35
- Phosphoproteomic analysis of Her2/neu signaling and inhibition
- Genomic Characterization of Primary Invasive Lobular Breast Cancer
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study